Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis
NCT07582146Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of acemetacin in axial spondyloarthritis (axSpA), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Pain Visual Analog Scale at 4 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
acemetacin
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT07582146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582146.